PlainPharmaWatch

CMS Open Payments · Program Year 2024

District of Columbia

District of Columbia received $26,446,161.89 in pharmaceutical-industry payments to 3,470 physicians and 7 teaching hospitals across 47,033 transactions.

$26.4M
Total payments
$20.6M
To physicians
$5.0M
To teaching hospitals
#32
of 59 states

In CMS Open Payments Program Year 2024, pharmaceutical and medical-device companies reported $26.4M in payments to 3,470 physicians and 7 teaching hospitals in District of Columbia. That ranks District of Columbia #32 of 59 states and territories (0.2% of the US total), averaging $5.9K per physician. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

The verdict

District of Columbia pairs below-median payment volume with a physician-heavy payment mix.

#32
of 59 states
0.2%
of the national total
77.7%
to physicians vs. hospitals
3,470
physicians paid

What the Data Shows for District of Columbia

District of Columbia splits Open Payments close to the corpus mid-mix: 77.7% to 3,470 physicians and 18.7% to 7 teaching hospitals, on $26.4M across 47,033 transactions.

Volume rank is #32 of 59: mid-pack dollars with the mix as the distinctive cut. Average transaction $562.29. Leading nature of payment: "Compensation for Services Other Than Consulting" at $6.6M (24.9% of the state file; top-three natures 63.2%).

District of Columbia sits in the 47th percentile (lower-volume tier). Just above: Nevada ($27.8M). Just below: Oklahoma ($24.3M). For context: top-ranked California ($342.4M) is 12.9× larger than District of Columbia. CMS Sunshine Act framework and methodology.

Physician vs Hospital Payments

How pharmaceutical payments in District of Columbia are distributed between physicians and teaching hospitals.

Physician Payments

$20.6M

77.7% of total · 3,470 recipients · $5.9K avg

Teaching Hospital Payments

$5.0M

18.7% of total · 7 hospitals · $708.0K avg

Payment Breakdown by Type

District of Columbia has 16 types of pharmaceutical payments. "Compensation for Services Other Than Consulting" accounts for 24.9%.

Nature concentration in District of Columbia

Top three Open Payments natures are 63.2% of state dollars; residual is every other reported nature

Compensation for Services Ot…$6.6MConsulting Fee$6.2MAcquisitions$4.0MAll other natures (13)$9.7M

Payment categories in District of Columbia

Top categories by total reported dollar volume

1. Compensation for Services…$6.6M2. Consulting Fee$6.2M3. Acquisitions$4.0M4. Grant$1.8M5. Travel and Lodging$1.8M6. Food and Beverage$1.5M7. Space Rental or Facility …$1.3M8. Education$971.1K9. Debt Forgiveness$663.4K10. Long-Term Medical Supply…$647.5K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $6.6M 1,852
Consulting Fee $6.2M 1,677
Acquisitions $4.0M 4
Grant $1.8M 44
Travel and Lodging $1.8M 4,324
Food and Beverage $1.5M 37,108
Space Rental or Facility Fees $1.3M 79
Education $971.1K 622
Debt Forgiveness $663.4K 84
Long-Term Medical Supply or Device Loan $647.5K 930
Royalty or License $485.3K 57
Honoraria $334.5K 113
Compensation for Faculty or Speaker (Medical Education) $145.5K 56
Gift $19.2K 77
Charitable Contribution $15.0K 1
Entertainment $141.11 5

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Source: CMS Open Payments Database Industry payments to physicians and teaching hospitals · 2024

What District of Columbia totals can and cannot tell you

The aggregate payment figure for District of Columbia measures reportable industry–physician engagement inside this state's geographic footprint for Program Year 2024, not any one physician's or hospital's relationship with industry. CMS collects the data under the Physician Payments Sunshine Act; manufacturers must report transfers of value above the de minimis threshold. The file does not capture DTC advertising, internal R&D, wholesale drug pricing, or salary support that is not a reportable transfer of value.

Correlations between payment receipt and prescribing appear in peer-reviewed work for specific drugs and specialties, but this page's state total does not establish causation. Open the company and recipient detail pages for category and year-over-year cuts.

View saved (states)
Download District of Columbia's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.